Biblio
“Trends, Predictors, and Outcomes of Healthcare Resources Used in Patients Hospitalized with Alzheimer's Disease with at Least One Procedure: The Nationwide Inpatient Sample.”, J Alzheimers Dis, vol. 57, no. 3, pp. 813-824, 2017.
, “The Link between Type 2 Diabetes and Neurodegeneration: Roles for Amyloid-β, Amylin, and Tau Proteins.”, J Alzheimers Dis, vol. 59, no. 2, pp. 421-432, 2017.
, “The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning?”, J Alzheimers Dis, vol. 64, no. s1, pp. S547-S554, 2018.
, “AβPP-Transgenic 2576 Mice Mimic Cell Type-Specific Aspects of Acetyl-CoA-Linked Metabolic Deficits in Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, “Sirtuin 2 Inhibition Improves Cognitive Performance and Acts on Amyloid-β Protein Precursor Processing in Two Alzheimer's Disease Mouse Models.”, J Alzheimers Dis, vol. 53, no. 3, pp. 1193-207, 2016.
, “The Instrumental Activity of Daily Living Profile in Aging: A Feasibility Study.”, J Alzheimers Dis, vol. 52, no. 4, pp. 1361-71, 2016.
, “Temporal Order of Alzheimer's Disease-Related Cognitive Marker Changes in BLSA and WRAP Longitudinal Studies.”, J Alzheimers Dis, vol. 59, no. 4, pp. 1335-1347, 2017.
, “Impact of Mild Cognitive Impairment on Mortality and Cause of Death in the Elderly.”, J Alzheimers Dis, vol. 64, no. 2, pp. 607-616, 2018.
, “Profiling of p5, a 24 Amino Acid Inhibitory Peptide Derived from the CDK5 Activator, p35 CDKR1 Against 70 Protein Kinases.”, J Alzheimers Dis, vol. 54, no. 2, pp. 525-33, 2016.
, “Analysis of the Inhibitory Elements in the p5 Peptide Fragment of the CDK5 Activator, p35, CDKR1 Protein.”, J Alzheimers Dis, 2015.
, “ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset.”, J Alzheimers Dis, vol. 79, no. 1, pp. 423-431, 2021.
, “Comparative Cognitive Effects of Choreographed Exercise and Multimodal Physical Therapy in Older Adults with Amnestic Mild Cognitive Impairment: Randomized Clinical Trial.”, J Alzheimers Dis, vol. 73, no. 2, pp. 769-783, 2020.
, “Superior Global Cognition in Oldest-Old Is Associated with Resistance to Neurodegenerative Pathologies: Results from The 90+ Study.”, J Alzheimers Dis, vol. 93, no. 2, pp. 561-575., 2023.
, “Passive Immunotherapy Targeting Tau Oligomeric Strains Reverses Tauopathy Phenotypes in Aged Human-Tau Mice in a Mouse Model-Specific Manner.”, J Alzheimers Dis, vol. 90, no. 3, pp. 1103-1122, 2022.
, “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
, “Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis.”, J Alzheimers Dis, vol. 62, no. 3, pp. 1199-1209, 2018.
, “Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 185-193, 2018.
, “Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cognition or Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 65, no. 3, pp. 781-791, 2018.
, “The Past and the Future of Alzheimer's Disease Fluid Biomarkers.”, J Alzheimers Dis, vol. 62, no. 3, pp. 1125-1140, 2018.
, “Intracerebroventricular Streptozotocin Induces Obesity and Dementia in Lewis Rats.”, J Alzheimers Dis, vol. 60, no. 1, pp. 121-136, 2017.
, “Intracranial Transplantation of Pancreatic Islets Attenuates Cognitive and Peripheral Metabolic Dysfunctions in a Rat Model of Sporadic Alzheimer's Disease.”, J Alzheimers Dis, vol. 65, no. 4, pp. 1445-1458, 2018.
, “Monitoring Blood-Brain Barrier Integrity Following Amyloid-β Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model.”, J Alzheimers Dis, vol. 54, no. 2, pp. 723-35, 2016.
, “Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 57, no. 2, pp. 387-393, 2017.
, “Alzheimer's Disease as the Product of a Progressive Energy Deficiency Syndrome in the Central Nervous System: The Neuroenergetic Hypothesis.”, J Alzheimers Dis, vol. 60, no. 4, pp. 1223-1229, 2017.
, “Cerebral Gray and White Matter Monogalactosyl Diglyceride Levels Rise with the Progression of Alzheimer's Disease.”, J Alzheimers Dis, vol. 95, no. 4, pp. 1623-1634, 2023.
,